Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.50 |
| ▸ | PLAU | P00749 | 3/20 | 0.50 |
| ▸ | PLG | P00747 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595480 | 0.90 | LMNA (0.51) | LMNATDP1SLC6A2SLC6A3KMT2A | |
| SCHEMBL7706207 | 0.86 | PLAU (0.54) | HDAC8HDAC6HDAC11HDAC1HDAC2 | |
| SCHEMBL3109875 | 0.86 | HDAC6 (0.61) | HDAC8HDAC6HDAC11HDAC1HDAC2 | |
| SCHEMBL30888879 | 0.84 | PLAU (0.57) | HDAC8HDAC6HDAC11HDAC1HDAC2 | |
| SCHEMBL15971036 | 0.84 | PLAU (0.57) | HDAC8HDAC6HDAC11HDAC1HDAC2 | |
| SCHEMBL23225464 | 0.83 | TDP1 (0.53) | LMNATDP1SLC6A2SLC6A3KMT2A | |
| SCHEMBL5069169 | 0.82 | PPARD (0.44) | LMNATDP1SLC6A2SLC6A3KMT2A | |
| SCHEMBL28247458 | 0.81 | PLAU (0.62) | HDAC8HDAC6HDAC11HDAC1HDAC2 | |
| SCHEMBL5068783 | 0.81 | TDP1 (0.54) | LMNATDP1SLC6A2SLC6A3KMT2A | |
| SCHEMBL5066704 | 0.81 | TDP1 (0.50) | LMNATDP1SLC6A2SLC6A3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| CN-101321726-A | Novel fused pyrrole derivative | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-12-10 | — | — | CN | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| CN-1067988-C | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 2001-07-04 | — | — | CN | disclosed |
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| CN-1051301-C | Indoloylguanidine derivatives | SUMITOMO PHARMA (JP) | 2000-04-12 | — | — | CN | disclosed |
| EP-0622356-B1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMA (JP) | 1998-07-01 | — | — | EP | disclosed |
| CN-1136038-A | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 1996-11-20 | — | — | CN | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| CN-1106800-A | Indoloylguanidine derivatives | SUMITOMO PHARMA (JP) | 1995-08-16 | — | — | CN | disclosed |
| EP-0622356-A1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | LMNA 4335/4885TDP1 4244/4885SLC6A2 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.